Volume 56, Issue 3, Pages (September 2009)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 58, Issue 3, Pages (September 2010)

Volume 380, Issue 9846, Pages (September 2012)

Volume 165, Issue 5, Pages (May 2001)

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study Ying Li, Sheng Zhang, Xi.

Volume 70, Issue 5, Pages (November 2016)

Volume 64, Issue 3, Pages (September 2013)

Volume 52, Issue 1, Pages (July 2007)

Volume 58, Issue 2, Pages (August 2010)

Volume 69, Issue 5, Pages (May 2016)

Volume 59, Issue 3, Pages (March 2011)

Volume 73, Issue 2, Pages (February 2018)

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 3, Pages (September 2015)

Volume 52, Issue 3, Pages (September 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 3, Pages (March 2007)

Volume 69, Issue 2, Pages (February 2016)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Ashish M. Kamat, Sima Porten European Urology

Volume 51, Issue 5, Pages (May 2007)

Volume 61, Issue 4, Pages (April 2012)

Volume 70, Issue 5, Pages (November 2016)

Volume 63, Issue 4, Pages (April 2013)

Volume 63, Issue 1, Pages (January 2013)

Volume 52, Issue 1, Pages (July 2007)

Volume 65, Issue 5, Pages (May 2014)

Bladder Cancer: A Major Public Health Issue

Volume 66, Issue 2, Pages (August 2014)

Nomograms for Bladder Cancer

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 61, Issue 4, Pages (April 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 67, Issue 3, Pages (March 2015)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 64, Issue 3, Pages (September 2013)

European Urology Oncology

Volume 56, Issue 6, Pages (December 2009)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 6, Pages (December 2011)

Volume 53, Issue 6, Pages (June 2008)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 70, Issue 2, Pages (August 2016)

Volume 47, Issue 1, Pages (January 2005)

The Economic Costs of Overactive Bladder in Germany

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 68, Issue 4, Pages (October 2015)

Volume 74, Issue 5, Pages (November 2018)

European Urology is “Your” Journal

Volume 68, Issue 5, Pages (November 2015)

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.

Volume 54, Issue 1, Pages (July 2008)

Volume 52, Issue 4, Pages (October 2007)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Volume 52, Issue 1, Pages (July 2007)

Volume 67, Issue 4, Pages (April 2015)

Volume 54, Issue 1, Pages (July 2008)

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Presentation transcript:

Volume 56, Issue 3, Pages 495-503 (September 2009) Single Postoperative Instillation of Gemcitabine in Patients with Non-muscle-invasive Transitional Cell Carcinoma of the Bladder: A Randomised, Double-blind, Placebo- controlled Phase III Multicentre Study Andreas Böhle, Herbert Leyh, Christian Frei, Michael Kühn, Reinhold Tschada, Tobias Pottek, Walter Wagner, Helmut H. Knispel, Wolfgang von Pokrzywnitzki, Ferruh Zorlu, Karin Helsberg, Birgit Lübben, Victoria Soldatenkova, Clemens Stoffregen, Hartwig Büttner European Urology Volume 56, Issue 3, Pages 495-503 (September 2009) DOI: 10.1016/j.eururo.2009.06.010 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Patient disposition. GEM=gemcitabine; PBO=placebo; CIS=carcinoma in situ. a Includes discontinuations because of clinical recurrence without histopathologic confirmation (GEM: one patient; PBO: two patients). European Urology 2009 56, 495-503DOI: (10.1016/j.eururo.2009.06.010) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier plot of recurrence-free survival.* CI=confidence interval; GEM=gemcitabine; PBO=placebo; HR=hazard ratio. * Noneligible patients were censored at baseline. European Urology 2009 56, 495-503DOI: (10.1016/j.eururo.2009.06.010) Copyright © 2009 European Association of Urology Terms and Conditions